Author:
Mandal P,Gupta A,Fusi-Rubiano W,Keane P A,Yang Y
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 387–401.
2. Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology 2015; 84 (15): 1582–1591.
3. Groves A, Kihara Y, Chun J . Fingolimod: direct CNS effects on sphingosine 1-phosphate (S1) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013; 328 (1–2): 9–18.
4. Chun J, Hartung H . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33 (2): 91–101.
5. NICE guidelines Fingolimod, SPC fingolimod joint Formulary Committee British National Formulary. 70th ed. BMJ Group and Pharmaceutical Press: London, UK, 2015.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献